Abiraterone-induced rhabdomyolysis resulting in acute kidney injury: A case report and review of the literature. (June 2018)

• Record Type: Journal Article
• Authors: Dineen, Michael; Hansen, Elizabeth; Guancial, Elizabeth; Sievert, Lynn; Sahasrabudhe, Deepak
• Is Part Of: Journal of oncology pharmacy practice. Volume 24:Number 4(2018)
• Page Start: 314
• Page End: 318
• Publication Date: 2018-06
• Subjects: Abiraterone -- rhabdomyolysis -- acute kidney injury -- statin; Cancer -- Chemotherapy -- Periodicals; Clinical pharmacology -- Periodicals; 616.994061
• DOI: 10.1177/1078155217701294
• Languages: English
• ISSNs: 1078-1552

Abstract

Abiraterone, a CYP17 inhibitor, blocks androgen biosynthesis in multiple tissue types. In combination with prednisone, it is approved as a first-line treatment for metastatic castration-resistant prostate cancer. We present a case of rhabdomyolysis associated with abiraterone therapy resulting in acute on chronic kidney injury in a patient with metastatic castration-resistant prostate cancer. Strict monitoring should be employed in patients started on abiraterone who have additional risk factors for developing rhabdomyolysis.